We are live on ! Find out more
GP

GSK plc Portfolio holdings

AUM $602M
This Fund
S&P 500
This Quarter Est. Return
+55.65%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$799M
AUM Growth
–
Cap. Flow
+$686M
Cap. Flow %
85.87%
Top 10 Hldgs %
97.88%
Holding
15
New
15
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 quarters
Top 10 Avg Time Held
0 quarters
Top 20 Avg Time Held
0 quarters

Top Buys

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$193M
2
WVE icon
Wave Life Sciences
WVE
+$185M
3
BNTX icon
BioNTech
BNTX
+$89.6M
4
VIR icon
Vir Biotechnology
VIR
+$50.9M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$42.5M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
WVE icon
1
Wave Life Sciences
WVE
$646M
$310M 38.82%
+18,245,691
New +$185M
2025 Q4
0 quarters
CRSP icon
2
CRISPR Therapeutics
CRSP
$4.98B
$169M 21.14%
+3,220,627
New +$193M
2025 Q4
0 quarters
BNTX icon
3
BioNTech
BNTX
$24.1B
$84.7M 10.6%
+889,824
New +$89.6M
2025 Q4
0 quarters
VIR icon
4
Vir Biotechnology
VIR
$1.91B
$51.6M 6.45%
+8,550,954
New +$50.9M
2025 Q4
0 quarters
LYEL icon
5
Lyell Immunopharma
LYEL
$203M
$46.6M 5.83%
+1,512,659
New +$33.9M
2025 Q4
0 quarters
IDYA icon
6
IDEAYA Biosciences
IDYA
$3.48B
$46.1M 5.77%
+1,333,333
New +$42.5M
2025 Q4
0 quarters
CYTK icon
7
Cytokinetics
CYTK
$8.73B
$21.6M 2.71%
+340,434
New +$21.2M
2025 Q4
0 quarters
SPRO icon
8
Spero Therapeutics
SPRO
$68.7M
$21.4M 2.68%
+9,190,606
New +$21.3M
2025 Q4
0 quarters
FULC icon
9
Fulcrum Therapeutics
FULC
$286M
$20.2M 2.53%
+1,785,714
New +$18.2M
2025 Q4
0 quarters
BCYC icon
10
Bicycle Therapeutics
BCYC
$266M
$10.8M 1.36%
+1,529,561
New +$11.3M
2025 Q4
0 quarters
CVRX icon
11
CVRx
CVRX
$39.4M
$7.15M 0.9%
+1,007,583
New +$9.2M
2025 Q4
0 quarters
NKTX icon
12
Nkarta
NKTX
$155M
$5.83M 0.73%
+3,150,732
New +$6.3M
2025 Q4
0 quarters
RGNX icon
13
Regenxbio
RGNX
$513M
$3.91M 0.49%
+271,456
New +$3.38M
2025 Q4
0 quarters
SENS icon
14
Senseonics Holdings Inc
SENS
$489M
$59.9K 0.01%
+10,856
New +$75.5K
2025 Q4
0 quarters
HBIO icon
15
Harvard Bioscience
HBIO
$37.5M
$7.46K ﹤0.01%
+1,115
New +$6.61K
2025 Q4
0 quarters

Similar funds

FIC
Family Investment Center Saint Joseph, Missouri $602M AUM 19.6% 1-Year Est. Return
WCA
Westover Capital Advisors Wilmington, Delaware $602M AUM 37.09% 1-Year Est. Return
PWP
Precedent Wealth Partners Houston, Texas $601M AUM 23.36% 1-Year Est. Return
F1I
Fund 1 Investments Rincon, Puerto Rico $603M AUM 62.42% 1-Year Est. Return
OPWM
Oakwell Private Wealth Management Austin, Texas $603M AUM 24.07% 1-Year Est. Return
FRM
Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return
PCTC
Perkins Coie Trust Company Seattle, Washington $603M AUM 23.96% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

GSK plc's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for GSK plc, which disclosed 15 positions worth $799M. Its ten largest holdings account for 98% of the portfolio.

Its largest position is CRISPR Therapeutics: 3,220,627 shares worth $169M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • GSK plc's largest Q4 2025 buy was CRISPR Therapeutics: 3,220,627 shares worth $169M.
  • GSK plc's ten largest holdings make up 98% of its $799M portfolio in Q4 2025.
  • GSK plc disclosed 15 positions in Q4 2025, its first 13F filing on record.

Based on GSK plc's 13F filing for Q4 2025, filed 12 Feb 2026.